European Commisson approves Elahere (mirvetuximab soravtansine) for FRα positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer – Abbvie
AbbVie announced the European Commission (EC) granted marketing authorization for Elahere (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous… read more.
